QualityStocks SUBMIT AN ARTICLE

BioDelivery Sciences International, Inc. (NASDQ: BDSI: Summary, Messages, Articles) announced that Niraj Vasisht, Ph.D. has been promoted to senior vice president of product development and chief technical officer.

“Dr. Vasisht has made an enormous contribution to the development of BDSI’s lead product, ONSOLIS, from the laboratory through clinical testing and regulatory review in the U.S. and Europe,” said Andrew Finn, executive vice president of product development. “Dr. Vasisht’s pharmaceutical development experience, capability and leadership are allowing BDSI to emerge as a leader in the use of drug delivery technologies to enhance pharmaceuticals for the benefits of patients.”

Dr. Vasisht is an internationally recognized expert in the field of microencapsulation and nanoencapsulation. He joined BDSI in 2005 as vice president of product development, and has been responsible for the development, manufacture and supply chain management of the company’s BioErodible MucoAdhesive (BEMA) and the pain treatment drug ONSOLIS, scheduled to be launched next year.

Chief Technical Officer is a newly created position within the company. In that capacity, Dr. Vasisht will help lead BDSI’s technical efforts in product formulation, development and manufacturing.

“The promotion of Dr. Vasisht to this role is an important step in BDSI’s plans to expand its portfolio of products using the BEMA drug delivery technology and to evaluate other applications, processes and technologies of interest,” said Finn, Pharm.D.

BioDelivery is a specialty pharmaceutical company focused on products to address pain treatment, using its own licensed patented drug delivery technologies to develop, partner and commercialize new products using proven therapeutics.

Let us hear your thoughts below: